


AN 130:24972 CA  
 TI Preparation of aryloxybenzenesulfonylhydroxycarboxamides as  
 metalloproteinase inhibitors.  
 IN Bender, Steven L.  
 PA Agouron Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850348	A1	19981112	WO 1998-US9389	19980508
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9872940	A1	19981127	AU 1998-72940	19980508
PRAI	US 1997-45931		19970509		
	WO 1998-US9389		19980508		
OS	MARPAT 130:24972				
GI					



AB Title compds. [I; Ar = aryl, heteroaryl; X = NHOH, OH; R<sup>1</sup> = H, CHR<sup>3</sup>R<sup>4</sup>, COR<sup>3</sup>, cycloalkyl, aryl, heteroaryl; R<sup>3</sup>, R<sup>5</sup> = H, suitable substituent; R<sup>4</sup>

=

H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R<sup>2</sup> = CH<sub>2</sub>R<sup>5</sup>, or R<sup>5</sup> and R<sup>4</sup> = (substituted) C atoms single- or double-bonded to one another], were prepd. Thus, (R)-2-pipecolic acid in CH<sub>2</sub>Cl<sub>2</sub> was treated sequentially with Me<sub>3</sub>SiCl, Et<sub>3</sub>N, and 4-(4-bromophenoxy)benzenesulfonyl chloride (prepn. given) in CH<sub>2</sub>Cl<sub>2</sub> to give (R)-1-[4-(4-bromophenoxy)benzenesulfonyl]piperidine-2-carboxylic acid. This in DMF was treated with N-methylmorpholine and BOP and then with NH<sub>2</sub>OH.HCl and addnl. N-methylmorpholine to give (R)-1-[4-(4-bromophenoxy)benzenesulfonyl]-N-hydroxypiperidine-2-carboxamide. The latter inhibited stromelysin with IC<sub>50</sub> = 0.04 nM.

IT 215921-26-9P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryloxybenzenesulfonylhydroxycarboxamides as metalloproteinase inhibitors)


RN 215921-26-9 CA

CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-[4-(1H-imidazol-2-yl)phenoxy]phenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemis




AN 85:108839 CA  
 TI Stereochemical studies. XL. A biomimetic conversion of L-lysine into optically active 2-substituted piperidines. Synthesis of D- and L-pipecolic acid, and (S)-(+)-coniine from L-lysine  
 AU Aketa, Kohichi; Terashima, Shiro; Yamada, Shunichi  
 CS Fac. Pharm. Sci., Univ. Tokyo, Tokyo, Japan  
 SO Chem. Pharm. Bull. (1976), 24(4), 621-31  
 CODEN: CPBTAL  
 DT Journal  
 LA English  
 GI



AB Deamination of L-H<sub>2</sub>N(CH<sub>2</sub>)<sub>4</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H.HCl with NaNO<sub>2</sub> and HCl followed by base gave the pipecolic acid I (R = R<sub>1</sub> = H) in >90% optically purity. Deamination of L-H<sub>2</sub>N(CH<sub>2</sub>)<sub>4</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H.1/2H<sub>2</sub>SO<sub>4</sub> with NaNO<sub>2</sub> and aq. H<sub>2</sub>SO<sub>4</sub> followed by chlorination with SOCl<sub>2</sub> and cyclization with aq. base gave its piperolic acid II (R = R<sub>1</sub> = H) in .apprx.80% optically purity. Precise estimation of optically activity was detd. by isolation of I (R = Me, R<sub>1</sub> = PhCH<sub>2</sub>O<sub>2</sub>C, p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>) and II (R = Me, R<sub>1</sub> = PhCH<sub>2</sub>O<sub>2</sub>C). I (R = R<sub>1</sub> = H) was converted to (S)(+)-coniine (III).  
 IT **60369-21-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and redn. of)  
 RN 60369-21-3 CA  
 CN 2-Piperidinepropanoic acid, 1-[(4-methylphenyl)sulfonyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



AN 125:104254 CA  
TI Oxadiazoles as **bioisosteric** transformations of  
**carboxylic** functionalities. II  
AU Andersen, K. E.; Lundt, B. F.; Joergensen, A. S.; Braestrup, C.  
CS Novo Nordisk A/S, Naaloev, 2760, Den.  
SO Eur. J. Med. Chem. (1996), 31(5), 417-425  
CODEN: EJMCA5; ISSN: 0223-5234  
DT Journal  
LA English  
OS CASREACT 125:104254  
AB To improve the in vivo efficacy of a series of known benzodiazepine  
receptor (BZR) ligands, 1-(2-phenyl-4-quinolinyl)-4-piperinecarboxamides,  
a series of analogs has been prepd. in which the amide group of these  
ligands has been replaced by a 1,2,4-oxadiazole moiety or converted to  
other carboxylic isosters such as esters or **nitriles**. An  
increase in the in vivo efficacy was obsd. for some of the compds. prepd.  
in this investigation compared to the parent carboxamide derivs.

AN 130:182353 CA  
 TI Preparation of 5-sulfamoylisatins as caspase inhibitors  
 IN Lee, Dennis; Long, Scott A.  
 PA SmithKline Beecham Corporation, USA  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906367	A1	19990211	WO 1998-US15935	19980730
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9887632	A1	19990222	AU 1998-87632	19980730
PRAI	US 1997-54255		19970730		
	WO 1998-US15935		19980730		
OS	MARPAT 130:182353				
GI					



AB Title compds. [I; R = SO<sub>2</sub>NR<sub>1</sub>R<sub>2</sub>; R<sub>1</sub> = H or alkyl; R<sub>2</sub> = (cyclo)alkyl, (hetero)arylalkyl, etc.; NR<sub>1</sub>R<sub>2</sub> = heterocyclyl; R<sub>3</sub>, R<sub>4</sub> = H, halo, NO<sub>2</sub>, alkyl; R<sub>5</sub> = H, alkyl, (hetero)arylalkyl] were prepd. Thus, 5-chlorosulfonylisatin was amidated by (S)-2-methoxymethylpyrrolidine to give I [R = (S)-2-methoxymethyl-1-pyrrolidinylsulfonyl, R<sub>3</sub>-R<sub>5</sub> = H]. Data for biol. activity of I were given.


IT **220510-40-7P**  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-sulfamoylisatins as caspase inhibitors)

RN 220510-40-7 CA



CN Pyrrolidine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl) sulfonyl]-2-(2-phenylethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 129:290149 CA  
 TI Preparation and formulation of biphenyl moiety-containing heterocyclic compounds as vasopressin antagonists  
 IN Ohtake, Yasuhiro; Naito, Akira; Naito, Kenji; Matsukawa, Hidehiko; Saito, Yoshiaki; Toyofuku, Hatsunori  
 PA Wakamoto Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 156 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843976	A1	19981008	WO 1997-JP4333	19971127
	W: AU, BR, CA, CN, IL, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9850674	A1	19981022	AU 1998-50674	19971127
PRAI	JP 1997-94460		19970331		
	WO 1997-JP4333		19971127		
OS	MARPAT 129:290149				
GI					



AB The title compds. I [A represents a single bond, CH<sub>2</sub>, CO, CS or SO<sub>2</sub>; B represents a single bond or CH<sub>2</sub>; R<sub>1</sub> represents hydrogen, OH, NR<sub>11</sub>R<sub>12</sub>

(wherein R1 and R2 independently represent each hydrogen or C1-4 alkyl),  
 OCOCH3 or halogen and R2 represents hydrogen, or R1 and R2 may form together oxo; and R3 represents hydrogen or C1-4 alkyl; the abs. configuration at the position a may be either R or S] are prepd. These compds. show low toxicity. In an in vitro test for affinity for the vasopressin V2 receptors, the pyrroloquinoxaline deriv. II showed IC50 of 0.00018 .mu.M.

IT 67488-67-9P 214144-32-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of biphenyl moiety-contg. heterocyclic compds. as vasopressin antagonists)

RN 67488-67-9 CA

CN 2-Pyrrolidineacetonitrile, 1-[(4-methylphenyl)sulfonyl]-, (2S)- (9CI)  
 (CA

INDEX NAME)

Absolute stereochemistry.




RN 214144-32-8 CA

CN 2-Pyrrolidineacetonitrile, 1-[(4-methylphenyl)sulfonyl]-, (2R)- (9CI)  
 (CA


INDEX NAME)

Absolute stereochemistry.





AN 89:215152 CA  
 TI Synthesis and circular dichroism of (5S)-1-azabicyclo[3.2.0]heptan-7-one  
 AU Busson, R.; Vanderhaeghe, H.  
 CS Rega Inst., Univ. Leuven, Louvain, Belg.  
 SO J. Org. Chem. (1978), 43(23), 4438-41  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 GI



AB The title compd. I (epi-1-carbapenam) was prepd. by cyclizing (2S)-2-pyrrolidylacetic acid. The optical purity of this homoproline, obtained for the first time in an active form, was shown by two independent preps. The CD curve of I showed a neg. Cotton effect at 231 nm with a shoulder at about 212 nm, which was compared to the CD of penicillanates.  
 IT **67488-67-9P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)  
 RN 67488-67-9 CA  
 CN 2-Pyrrolidineacetonitrile, 1-[(4-methylphenyl)sulfonyl]-, (2S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

